#USA #Cambridge #Biopharma #Zifo #DMTA

Introduction

In a recent position paper, Zifo, a leader in AI and data-driven enterprise informatics, articulates an urgent need for biopharma companies to rethink their current Design-Make-Test-Analyse (DMTA) workflows. The traditional approach has been recognized as a DMTA doom loop, where experiments are fragmented and disconnected, hampering overall efficiency and learning. Zifo proposes a paradigm shift towards an interconnected network that adapts to scientists' needs, underscoring the importance of maintaining context and continuity throughout the scientific process.

The DMTA Doom Loop

The DMTA doom loop highlights a fundamental flaw in the existing biopharma processes, where scientific efforts are forced into a linear and sequential execution model. This inflexibility often results in disconnected experiments, fragmented evidence, and manual reconciliation of data, which collectively decelerate progress across the scientific value chain. Zifo argues that to break free from this cycle, biopharma firms must evolve their workflows into a connected scientific network.

Towards a Connected Scientific Network

Zifo envisions a redefined DMTA cycle that emphasizes flexibility and responsiveness. By shifting from a linear series of handoffs to a connected and agile network, researchers can conduct experiments in varying orders, adapt processes as needed, and ensure that scientific context travels seamlessly with every sample, result, and decision. The proposed interconnected learning cycle aims to integrate all components of the scientific methodology rather than isolating them into separate functions.

The Current Landscape: Fragmented Data and Lost Context

In many biopharma environments, the evidence generated from experiments is scattered across various platforms, applications, and individual expertise. This fragmentation necessitates extensive data reconciliation, reconstruction of sample histories, and retrieval of previous decision-making processes. The heart of the problem lies not just in the disjointed data but in the loss of critical scientific context each time information transitions between systems or teams. The result is an operational DMTA cycle that fails to function effectively due to a lack of coherent context.

Enhancing the Scientist Experience

One of the significant barriers affecting the DMTA process is the inadequate user experience for scientists. Traditional IT ecosystems within the biopharma industry are often designed primarily for compliance and data architecture requirements, making everyday workflows arduous for scientists. Zifo’s position paper emphasizes the need to rethink the scientific user experience by adopting an orchestration layer to facilitate better connectivity and usability across existing systems.

The Importance of Integrated Workflows

Zifo warns against merely digitizing current fragmented workflows or introducing isolated applications. Transformative change cannot occur simply by shifting inefficient methods from paper to digital templates; instead, biopharma must reimagine the DMTA process entirely. This demands innovative thinking to create a cohesive scientific workflow that encompasses interconnected data structures, allowing scientists to navigate between steps organically.

Principles of the Proposed Model

The new model outlined by Zifo is based on several key principles:

• - Scientists should be able to traverse and jump between steps as necessary, promoting a more agile workflow.
• - Historical data and evidence must be readily accessible when designing experiments.
• - Context and intent must remain connected to samples, ensuring clarity in results interpretation.
• - Test results should retain their connections to previous methodologies, conditions, and materials.
• - Decisions made should be traceable and linked to both results and their foundational reasoning.

These principles represent a significant departure from isolated systems, advocating for a seamlessly integrated scientific context that fosters collaboration and knowledge sharing.

Orchestration Layer: Connecting Efforts for Greater Impact

Rather than proposing a singular solution, Zifo advocates for the implementation of an orchestration layer that integrates current scientific activities across different existing systems. This approach respects validated core systems while providing scientists with the context needed for specific tasks. The orchestrated environment would aggregate evidence and facilitate seamless information capture and reuse across the DMTA network, thus alleviating the burden placed on researchers.

Rethinking User Experience for Scientists

Improvements in user experience must transcend the outdated one-size-fits-all templates in favor of smaller, modular components tailored to the evolving needs of scientists. The objective is to provide a digital workspace that adapts to immediate demands, enhancing scientists' ability to work efficiently without unnecessary constraints.

From Completing Experiments to Compounding Knowledge

Ultimately, adopting a connected DMTA network aims to transform the objective from simply moving experiments through functional stages to actively increasing organizational knowledge with each test or experiment. This necessitates a collaborative approach involving various functions such as CMC, process development, and IT, ensuring that every flow of experimental evidence contributes meaningfully to the overall scientific inquiry.

Conclusion

Zifo's insights present a roadmap for biopharma companies looking to overcome the limitations of traditional DMTA workflows by promoting a more integrated and agile approach to scientific work. By focusing on orchestrating existing systems, prioritizing user experience, and fostering continual knowledge compounds, the biopharma industry can advance more effectively in addressing the complex challenges it faces today. To delve deeper into Zifo's perspective, download the full position paper at this link.